The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
PARTNER is a prospective, phase II–III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer1, 2, who were germline BRCA1 and BRCA2 wild type3. Here we report the results of the trial. Patients (n = 559) were randomized on a 1:1 basis to receive neoadjuvant...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Nature Research
2024
|
| _version_ | 1811140197324161024 |
|---|---|
| author | Abraham, JE Pinilla, K Dayimu, A Grybowicz, L Demiris, N Harvey, C Drewett, LM Lucey, R Fulton, A Roberts, AN Worley, JR Chhabra, A Qian, W Vallier, A Hardy, RM Chan, S Hickish, T Tripathi, D Venkitaraman, R Persic, M Aslam, S Glassman, D Raj, S Borley, A Levitt, NC |
| author_facet | Abraham, JE Pinilla, K Dayimu, A Grybowicz, L Demiris, N Harvey, C Drewett, LM Lucey, R Fulton, A Roberts, AN Worley, JR Chhabra, A Qian, W Vallier, A Hardy, RM Chan, S Hickish, T Tripathi, D Venkitaraman, R Persic, M Aslam, S Glassman, D Raj, S Borley, A Levitt, NC |
| author_sort | Abraham, JE |
| collection | OXFORD |
| description | PARTNER is a prospective, phase II–III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer1, 2, who were germline BRCA1 and BRCA2 wild type3. Here we report the results of the trial. Patients (n = 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin–paclitaxel with or without 150 mg olaparib twice daily, on days 3 to 14, of each of four cycles (gap schedule olaparib, research arm) followed by three cycles of anthracycline-based chemotherapy before surgery. The primary end point was pathologic complete response (pCR)4, and secondary end points included event-free survival (EFS) and overall survival (OS)5. pCR was achieved in 51% of patients in the research arm and 52% in the control arm (P = 0.753). Estimated EFS at 36 months in the research and control arms was 80% and 79% (log-rank P > 0.9), respectively; OS was 90% and 87.2% (log-rank P = 0.8), respectively. In patients with pCR, estimated EFS at 36 months was 90%, and in those with non-pCR it was 70% (log-rank P < 0.001), and OS was 96% and 83% (log-rank P < 0.001), respectively. Neoadjuvant olaparib did not improve pCR rates, EFS or OS when added to carboplatin–paclitaxel and anthracycline-based chemotherapy in patients with triple-negative breast cancer who were germline BRCA1 and BRCA2 wild type. ClinicalTrials.gov ID: NCT03150576. |
| first_indexed | 2024-09-25T04:18:09Z |
| format | Journal article |
| id | oxford-uuid:f5fb04be-f125-4ff9-a380-7f23cce27878 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-09-25T04:18:09Z |
| publishDate | 2024 |
| publisher | Nature Research |
| record_format | dspace |
| spelling | oxford-uuid:f5fb04be-f125-4ff9-a380-7f23cce278782024-07-20T16:22:46ZThe PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancerJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f5fb04be-f125-4ff9-a380-7f23cce27878EnglishJisc Publications RouterNature Research2024Abraham, JEPinilla, KDayimu, AGrybowicz, LDemiris, NHarvey, CDrewett, LMLucey, RFulton, ARoberts, ANWorley, JRChhabra, AQian, WVallier, AHardy, RMChan, SHickish, TTripathi, DVenkitaraman, RPersic, MAslam, SGlassman, DRaj, SBorley, ALevitt, NCPARTNER is a prospective, phase II–III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer1, 2, who were germline BRCA1 and BRCA2 wild type3. Here we report the results of the trial. Patients (n = 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin–paclitaxel with or without 150 mg olaparib twice daily, on days 3 to 14, of each of four cycles (gap schedule olaparib, research arm) followed by three cycles of anthracycline-based chemotherapy before surgery. The primary end point was pathologic complete response (pCR)4, and secondary end points included event-free survival (EFS) and overall survival (OS)5. pCR was achieved in 51% of patients in the research arm and 52% in the control arm (P = 0.753). Estimated EFS at 36 months in the research and control arms was 80% and 79% (log-rank P > 0.9), respectively; OS was 90% and 87.2% (log-rank P = 0.8), respectively. In patients with pCR, estimated EFS at 36 months was 90%, and in those with non-pCR it was 70% (log-rank P < 0.001), and OS was 96% and 83% (log-rank P < 0.001), respectively. Neoadjuvant olaparib did not improve pCR rates, EFS or OS when added to carboplatin–paclitaxel and anthracycline-based chemotherapy in patients with triple-negative breast cancer who were germline BRCA1 and BRCA2 wild type. ClinicalTrials.gov ID: NCT03150576. |
| spellingShingle | Abraham, JE Pinilla, K Dayimu, A Grybowicz, L Demiris, N Harvey, C Drewett, LM Lucey, R Fulton, A Roberts, AN Worley, JR Chhabra, A Qian, W Vallier, A Hardy, RM Chan, S Hickish, T Tripathi, D Venkitaraman, R Persic, M Aslam, S Glassman, D Raj, S Borley, A Levitt, NC The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer |
| title | The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer |
| title_full | The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer |
| title_fullStr | The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer |
| title_full_unstemmed | The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer |
| title_short | The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer |
| title_sort | partner trial of neoadjuvant olaparib with chemotherapy in triple negative breast cancer |
| work_keys_str_mv | AT abrahamje thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT pinillak thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT dayimua thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT grybowiczl thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT demirisn thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT harveyc thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT drewettlm thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT luceyr thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT fultona thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT robertsan thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT worleyjr thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT chhabraa thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT qianw thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT valliera thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT hardyrm thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT chans thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT hickisht thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT tripathid thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT venkitaramanr thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT persicm thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT aslams thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT glassmand thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT rajs thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT borleya thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT levittnc thepartnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT abrahamje partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT pinillak partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT dayimua partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT grybowiczl partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT demirisn partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT harveyc partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT drewettlm partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT luceyr partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT fultona partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT robertsan partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT worleyjr partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT chhabraa partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT qianw partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT valliera partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT hardyrm partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT chans partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT hickisht partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT tripathid partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT venkitaramanr partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT persicm partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT aslams partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT glassmand partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT rajs partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT borleya partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer AT levittnc partnertrialofneoadjuvantolaparibwithchemotherapyintriplenegativebreastcancer |